

# Cath Lab Digest

A product, news & clinical update for the cardiac catheterization laboratory specialist



## CATH LAB ERGONOMICS

### Removing Occupational Hazards for Healthcare Providers: The GLift PRO

CLD talks with Matthew B. O'Steen, MD.

#### Can you tell us about your practice?

I am an interventional cardiologist with Coastal Cardiology, a private practice group in Charleston, South Carolina. We are mainly affiliated with Roper St. Francis Healthcare. Our group has 10 cardiologists and 8 physician assistants, with a fairly busy practice. I do coronary work, some peripherals, Watchman (Boston Scientific) procedures, MitraClip (Abbott Vascular) procedures, and chronic total occlusion revascularization, so sometimes I am doing longer cases.

#### Can you tell us about the GLift PRO system?

*continued on page 16*

## In This Issue

### LM PCI in Interventional Labs Without On-Site Surgery: When is High Risk Too High?

Morton Kern, MD, with Kirk Garratt, MD, MSc, Bonnie Weiner, MD, MSEC, MBA, and Christopher White, MD  
**page 6**

### Considerations for Pretreatment in PCI for NSTEMI-ACS

Shailendra Singh, MD  
**page 18**

### Unplugged: A Left Atrial Appendage Leak

Bernadette S. Speiser, BSN, MSN, CCRN, RCIS; Patrick Burchfiel, MA, BSN, CEN; Jessica Finster, RN, BSN  
**page 23**


## CASE REPORT

### Re-Defining Balloon Uncrossable

Yasin Hussain, MD; Samit Shah, MD, PhD, FACC, FSCAI

#### Background

Complex coronary interventions for calcified lesions or critical stenoses often require atherectomy for plaque modification to allow delivery of standard balloon catheters. However, the risk of atherectomy can be high in aorto-ostial lesions, tortuous or small caliber vessels, or hemodynamically unstable patients. The Takeru PTCA Balloon Dilation Catheter, (Terumo Interventional Systems), is a new alternative to address lesions that had historically been considered “balloon uncrossable.” Available in semi-compliant, non-compliant, and over-the-wire options with diameters from 1.5 to 4.0 mm, the Takeru balloon has a smaller crossing profile and tighter re-wrap than many other balloons on the market. As a result, our catheterization laboratory has transitioned to using the Takeru balloon as our first-line angioplasty balloon.



*continued on page 12*


## CASE REPORT

### The “Tip In” Technique

Zaheed Tai, DO

#### History

The patient is a 76-year-old gentleman with a history of coronary artery disease, hyperlipidemia, hypertension, diabetes, and vascular disease. He had previously undergone revascularization of the right lower extremity in-stent chronic total occlusion. He has been experiencing recurrent lifestyle-limiting claudication, and presented for angiography and revascularization.



*continued on page 14*

Continued from cover

# Re-Defining Balloon Uncrossable

Yasin Hussain, MD; Samit Shah, MD, PhD, FACC, FSCAI

## Clinical Case

A 77-year-old man with hypertension, hyperlipidemia, diabetes mellitus, and chronic kidney disease stage 3 presented to our hospital with progressive angina. He underwent stress testing that showed an area of inferior ischemia as well as transient ischemic dilatation concerning for multivessel coronary artery disease. Diagnostic coronary angiography showed severe calcific disease of the left anterior descending artery (LAD), a diffusely diseased left circumflex (LCx), and a critical ostial stenosis of the right coronary artery (RCA) (Figure 1A-C). The patient was evaluated for coronary artery bypass graft surgery but determined


to be at prohibitive risk for open heart surgery. We proceeded with planned multivessel percutaneous coronary intervention in staged sessions due to the patient's underlying kidney disease.

## Procedure

We proceeded with intervention to the RCA via right radial access using a 6 French (Fr) Terumo Glidesheath. Due to the critical ostial stenosis, a Terumo Runthrough wire was loaded in a 6 Fr Judkins right (JR)4 guide. There was severe pressure dampening on guide engagement and the wire was quickly advanced into the distal RCA. We attempted to deliver 2.5 and 2.0 mm Takeru semi-compliant

IVUS showed well-expanded and well-apposed stents without evidence of dissection (Figure 3B), and the ostial RCA minimal stent area was 10mm<sup>2</sup>. The entire intervention was performed with only 65 mL of contrast dye.


balloons, but the balloons would not cross the proximal RCA stenoses. We then used a 1.5 mm Takeru semi-compliant balloon and dilated the ostial and proximal RCA, followed by 2.0 and 2.5 mm noncompliant balloons at 14 atmospheres (atm)




**Figure 1.** Diagnostic coronary angiography demonstrated severe multi-vessel coronary artery disease, including severe calcified disease of the left anterior descending (LAD) coronary artery (A), diffuse disease of the left circumflex (LCx) artery (B), and critical stenosis of the ostial and proximal right coronary (RCA) (C).



**Figure 2.** After dilating the proximal RCA with a Takeru 1.5 mm x 15 mm semi-compliant balloon (Terumo), the vessel was further dilated with 2.0 mm x 15 mm and 2.5 mm x 15 mm noncompliant balloons.



**Figure 3.** Intravascular ultrasound demonstrated severe disease of the proximal RCA with deep calcification (A). After further vessel preparation with a cutting balloon, stents were deployed and post dilated, yielding excellent expansion (B).



**Figure 4.** There was an excellent angiographic result in the RCA (A) and the patient returned for staged intervention with rotational atherectomy and intravascular lithotripsy (Shockwave Medical) to the LAD (B).

(Figure 2). The ostial lesion was further dilated with a 2.5 x 10 mm Wolverine cutting balloon (Boston Scientific) at 8 atm. Intravascular ultrasound (IVUS) was performed with a Refinity catheter (Philips) (Figure 3A), and using a 6 Fr Guideliner (Teleflex), 2.5 mm x 38 mm and 2.5 mm x 22 mm Onyx Frontier drug-eluting stents (Medtronic) were deployed from the ostium to the mid RCA at 12 atm. The stents were post dilated with 3.0 and 3.5 mm Takeru noncompliant balloons at 18 atm. There was an excellent angiographic result with no residual stenosis (Figure 4A). IVUS showed

well-expanded and well-apposed stents without evidence of dissection (Figure 3B), and the ostial RCA minimal stent area was 10mm<sup>2</sup>. The entire intervention was performed with only 65 mL of contrast dye. The patient was maintained on dual antiplatelet therapy with aspirin 81 mg and clopidogrel 75 mg daily. The patient returned for staged intervention to the LAD with rotational atherectomy and intravascular lithotripsy (Shockwave Medical) (Figure 4B). ■

*This case is supported by Terumo Interventional Systems.*

#### **Yasin Hussain, MD**

*Interventional Cardiology Fellow, Yale School of Medicine, Yale New Haven Hospital, New Haven, Connecticut*

#### **Samit Shah, MD, PhD, FACC, FSCAI**

*Director, VA Connecticut Cardiac Catheterization Laboratory, Assistant Professor of Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut*



*Dr. Hussain can be contacted at [yasin.hussain@yale.edu](mailto:yasin.hussain@yale.edu) and Dr. Shah can be contacted at [samit.shah@yale.edu](mailto:samit.shah@yale.edu)*

View the article online by scanning the QR code with your smartphone camera.



## SELECTED MEETINGS CALENDAR

### APRIL 25-27

#### **Charing Cross Symposium (CX) 2023**

Hilton London Metropole, London, U.K.  
[cxsymposium.com](http://cxsymposium.com)

### MAY 10-13

#### **The Venous Symposium**

Sheraton New York Times Square Hotel, New York City, New York  
[venous-symposium.com](http://venous-symposium.com)

### MAY 10-13

#### **28th Annual Interventional Cardiology Fellows Course**

Caribe Royale Orlando, Orlando, Florida  
[fellows2023.crfconnect.com/register](http://fellows2023.crfconnect.com/register)

### MAY 16-19

#### **EuroPCR**

Palais des congrès, Paris, France  
[pcronline.com/courses/europcr](http://pcronline.com/courses/europcr)

### MAY 18-20

#### **Outpatient Endovascular and Interventional Society (OEIS) 2023 Annual Meeting**

Coronado Springs Resort, Lake Buena Vista, Florida  
[oisweb.com/meetings/annual-meeting-2023](http://oisweb.com/meetings/annual-meeting-2023)

### MAY 18-20

#### **Society for Cardiovascular Angiography and Interventions (SCAI) 2023 Scientific Sessions**

Phoenix Convention Center, Phoenix, Arizona  
[scai.org/scai-2023-scientific-sessions](http://scai.org/scai-2023-scientific-sessions)

### MAY 30-JUNE 2

#### **2023 New CardioVascular Horizons (NCVH) Annual Conference**

The Roosevelt New Orleans, New Orleans, Louisiana  
[ncvh.org/ncvh-2023](http://ncvh.org/ncvh-2023)

### JUNE 6-9

#### **\*Leipzig Interventional Course (LINC) 2023**

Messe Leipzig, Leipzig, Germany  
[leipzig-interventional-course.com](http://leipzig-interventional-course.com)

### AUGUST 16-19

#### **\*The Amputation Prevention Symposium (AMP)**

Sheraton Grand Chicago Riverwalk, Chicago, Illinois  
[amptheclimeeting.com](http://amptheclimeeting.com)

### OCTOBER 23-26

#### **Transcatheter Cardiovascular Therapeutics (TCT) 2023**

Moscone Center, San Francisco, California  
[tct2023.crfconnect.com](http://tct2023.crfconnect.com)

*\*An HMP Global meeting. Cath Lab Digest is published by HMP Global.*